www.vectorlabs.com
Email: customerservice@vectorlabs.com
Telephone: (650) 697-3600

CY5.5 DBCO

SKU: CCT-1046



DESCRIPTION

Cy5.5 DBCO is a bright and photostable near-IR probe that spectrally similar to Alexa Fluor® 680, DyLight® 680, and IRDye® 680 dye. The Cy5.5 DBCO is water-soluble, hydrophilic dye often a reagent of choice for assay where minimal non-specific binding and exceptional brightness is required. The fluorescence of Cy5.5 DBCO is pH insensitive from pH 4 to pH 10 and produces minimal autofluorescence of biological specimens in this region of the spectrum. Fluorescence of this long-wavelength Cyanine dye is not visible to the human eye but is readily detected by most imaging systems.

Cy5.5 DBCO reacts with azides via a copper-free “click chemistry” reaction to form a stable triazole and does not require Cu-catalyst or elevated temperatures. In application where the presence of copper is a concern Cy5.5 DBCO is an ideal alternative to copper requiring fluorescent alkynes.

Cy5.5 DBCO reagent is not suitable for staining intracellular components of fixed and permeabilized cells due to high backgrounds.

For research use only. Not intended for therapeutic or diagnostic use in animals or humans.

www.vectorlabs.com
Email: customerservice@vectorlabs.com
Telephone: (650) 697-3600

SPECIFICATIONS

CAS Number	1857352-95-4
Molecular Weight	1161.34
Appearance	Blue solid
Extinction Coefficient	190,000
Purity	>95% (HPLC)
Unit Size	1 mg, 5 mg, 25 mg, 100 mg
Solubility	Water, DMSO, DMF
Storage Instructions	-20°C. Desiccate
Spectrally Similar Dyes	Alexa Fluor® 680, IRDye® 680RD, DyLight® 680
Excitation/Emission Maximum	678/694 nm
Shipping Conditions	Ambient temperature
Shipping Instructions	Ambient temperature

ABS/EM SPECTRA



For research use only. Not intended for therapeutic or diagnostic use in animals or humans.

SELECTED REFERENCES

1. Lancien, M., *et al.* (2020). A snake toxin as a theranostic agent for the type 2 vasopressin receptor. *Theranostics.*, **10 (25)**, 11580-11594. [PubMed]
2. Wang X., *et al.* (2021). Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer. *ACS Chem. Biol.,* **16 (4)**, 724-730. [PubMed]

DOCUMENTS

- Safety Data Sheet
- Download CoA
- Datasheet

GALLERY IMAGES



For research use only. Not intended for therapeutic or diagnostic use in animals or humans.